MGCD265 dihydrochloride - Glesatinib dihydrochloride | MG265 dihydrochloride

Based on 17 reference(s) in Google Scholar 8 10 17

Axon 3975

CAS [N.A.]

MF C31H27F2N5O3S2.2HCl
MW 692.63

  • Purity: 99%
  • Soluble in DMSO

MGCD265 dihydrochloride


MGCD265 is an orally bioavailable, multitargeted tyrosine kinase inhibitor. It binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). It is currently being evaluated clinically in patients with solid tumors that have genetic alterations in MET or AXL genes, which have been implicated as drivers of tumor growth and disease progression in NSCLC, gastroesophageal cancer and other solid tumors.

KEYWORDS: MGCD265 dihydrochloride | Supplier | MET/SMO dual inhibitor. | Glesatinib dihydrochloride | MG265 dihydrochloride | MGCD-265 | MGCD 265 | MG-265 | MG 265 | CT-MG265 | CAS [N.A.] | [936694-12-1] | HGF | c-MET | SMO | Inhibitor | Receptors

Orally active, potent MET/SMO dual inhibitor

Chemical name


Source information

Sold in collaboration with Chemietek

Parent CAS No.


Size Unit Price Stock
5 mg €130.00 In Stock
25 mg €460.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...